Related references
Note: Only part of the references are listed.Effects of 3 years of lasofoxifene treatment on bone turnover markers in women with postmenopausal osteoporosis
Richard Eastell et al.
BONE (2012)
Relationships Between Changes in Bone Mineral Density or Bone Turnover Markers and Vertebral Fracture Incidence in Patients Treated with Bazedoxifene
Olivier Bruyere et al.
CALCIFIED TISSUE INTERNATIONAL (2012)
Relationship of changes in total hip bone mineral density to vertebral and nonvertebral fracture risk in women with postmenopausal osteoporosis treated with once-yearly zoledronic acid 5 mg: The HORIZON-Pivotal Fracture Trial (PFT)
Richard M. Jacques et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2012)
Sustained efficacy and safety of bazedoxifene in preventing fractures in postmenopausal women with osteoporosis: results of a 5-year, randomized, placebo-controlled study
S. L. Silverman et al.
OSTEOPOROSIS INTERNATIONAL (2012)
Bisphosphonates for postmenopausal osteoporosis
Richard Eastell et al.
BONE (2011)
Arzoxifene for Prevention of Fractures and Invasive Breast Cancer in Postmenopausal Women
Steven R. Cummings et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2011)
Osteoporosis: now and the future
Tilman D. Rachner et al.
LANCET (2011)
Markers of bone turnover for the prediction of fracture risk and monitoring of osteoporosis treatment: a need for international reference standards
S. Vasikaran et al.
OSTEOPOROSIS INTERNATIONAL (2011)
Vertebral fracture assessment using a semiquantitative technique
Harry K. Genant et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2010)
Lasofoxifene in Postmenopausal Women with Osteoporosis
Steven R. Cummings et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Effects of Yearly Zoledronic Acid 5 mg on Bone Turnover Markers and Relation of PINP With Fracture Reduction in Postmenopausal Women With Osteoporosis
Pierre D. Delmas et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2009)
Denosumab for Prevention of Fractures in Postmenopausal Women with Osteoporosis
Steven R. Cummings et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Bone turnover markers: understanding their value in clinical trials and clinical practice
R. Civitelli et al.
OSTEOPOROSIS INTERNATIONAL (2009)
Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis
Dennis M. Black et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Raloxifene reduces fractures in postmenopausal women with osteoporosis
Jean-Yves Reginster et al.
CLINICAL ORTHOPAEDICS AND RELATED RESEARCH (2006)
Relationship between changes in biochemical markers of bone turnover and BMD to predict vertebral fracture risk
S Sarkar et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2004)
Change in bone turnover and hip, non-spine, and vertebral fracture in alendronate-treated women: The Fracture Intervention Trial
DC Bauer et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2004)
Randomized trial of effect of alendronate continuation versus discontinuation in women with low BMD: Results from the Fracture Intervention Trial long-term extension
KE Ensrud et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2004)
Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis
CH Chesnut et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2004)
Insufficiently dosed intravenous ibandronate injections are associated with suboptimal antifracture efficacy in postmenopausal osteoporosis
R Recker et al.
BONE (2004)
Relationship of early changes in bone resorption to the reduction in fracture risk with risedronate
R Eastell et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2003)
Effect of risedronate on the risk of hip fracture in elderly women
MR McClung et al.
NEW ENGLAND JOURNAL OF MEDICINE (2001)
Alendronate for the treatment of osteoporosis in men
E Orwoll et al.
NEW ENGLAND JOURNAL OF MEDICINE (2000)
Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis
JY Reginster et al.
OSTEOPOROSIS INTERNATIONAL (2000)
Share Paper
